FibroBiologics Reports Net Loss Due to R&D Expenses in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy FBLG?
The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expenses. Pete O'Heeron, CEO, and Founder of FibroBiologics commented, "During the first quarter of 2026, we made important progress initiating our phase 1/2 clinical trial, including completing cGMP manufacturing of the first batch of the CYWC628 drug product and site onboarding to support dosing the first patient in the second quarter. We continued to build momentum across our pipeline, with positive preclinical data in both our burn and degenerative disc disease programs, further supporting the potential of our fibroblast-based platform. We also strengthened our cash position with additional capital. As we move into the next phase of execution, our focus is on initiating our clinical study, generating meaningful data, and advancing our pipeline programs in psoriasis and multiple sclerosis."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBLG
Wall Street analysts forecast FBLG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.320
Low
1.50
Averages
3.25
High
5.00
Current: 1.320
Low
1.50
Averages
3.25
High
5.00
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FibroBiologics Presents Psoriasis Data at SID 2026
- Clinical Stage Progress: FibroBiologics presents preclinical data from its CYPS317 program for psoriasis at the 2026 Society for Investigative Dermatology Annual Meeting, highlighting the company's ongoing R&D efforts in psoriasis treatment, which is expected to enhance its competitiveness in the biotechnology sector.
- Patent Advantage: With over 270 issued and pending patents covering various chronic disease treatments, the company demonstrates its innovative capabilities in cell therapy and tissue regeneration, potentially laying the groundwork for future market expansion.
- Conference Details: Senior Scientist Dr. Chuo Fang will present at the annual meeting in Chicago on May 15, 2026, from 4:30 p.m. to 6:00 p.m., further elevating the company's profile in the academic community.
- Strategic Positioning: By showcasing preclinical data, FibroBiologics not only highlights its potential in psoriasis treatment but may also attract investor interest, facilitating future funding inflows to support its R&D projects.
See More
FibroBiologics Reports Q1 2026 Financial Results and Corporate Update
- Clinical Trial Progress: FibroBiologics has completed the manufacturing of the first two batches of the CYWC628 drug product in compliance with FDA cGMP, laying the groundwork for the phase 1/2 clinical trial for diabetic foot ulcers, with patient dosing expected to commence in Q2 2026.
- Positive Preclinical Results: The company reported promising preclinical outcomes in its burn program using proprietary fibroblast spheroid technology, indicating an increase in tissue repair cytokines and a significant reduction in inflammation drivers, suggesting strong therapeutic potential for future clinical applications.
- Funding and Compliance: FibroBiologics raised $3 million through a direct offering and secured an additional $2.5 million post-March 31, 2026, successfully regaining compliance with Nasdaq listing requirements, thereby enhancing the company's financial stability.
- Patent Portfolio Expansion: The company has expanded its patent portfolio with new patents covering fibroblast cell therapy for osteoporosis and a novel fibroblast-based treatment for cachexia, further solidifying its intellectual property in the biotechnology sector and supporting future product development.
See More
FibroBiologics Reports Q1 2026 Financial Results with $5M Loss
- Financial Loss Overview: FibroBiologics reported a net loss of approximately $5 million for the three months ended March 31, 2026, primarily due to increased research and development and administrative expenses, indicating ongoing investment in technology development amid financial pressure.
- Cash Flow Status: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, reflecting tight operational funding that may impact future research and operational capabilities.
- Financing Activities: After March 31, 2026, FibroBiologics raised approximately $2.5 million net through a registered direct offering, aimed at enhancing liquidity and supporting ongoing operations.
- Nasdaq Compliance: FibroBiologics successfully met Nasdaq's $2.5 million equity rule through a combined unit offering priced at $4.40 and a 1-for-20 reverse split, ensuring compliance in the capital markets.
See More
FibroBiologics Advances Phase 1/2 Clinical Trial for CYWC628
- Clinical Trial Launch: FibroBiologics is on track to dose the first patient with CYWC628 for diabetic foot ulcers in Q2 2026, marking a significant milestone in its clinical development and potentially enhancing its market position in chronic disease treatments.
- Manufacturing Compliance: The company has completed the production of the first two batches of CYWC628 in accordance with FDA Good Manufacturing Practices (cGMP), ensuring product quality and laying a solid foundation for the upcoming clinical trials.
- Financial Position Improvement: FibroBiologics raised $3 million through a direct offering in Q1 2026, bolstering its cash flow, and despite an increase in R&D expenses to $3 million, the company remains compliant, reflecting robust financial management.
- Patent Portfolio Expansion: The company has secured new patents for treatments targeting osteoporosis and cachexia, further strengthening its intellectual property in cell therapy, which is expected to provide significant support for future product development and market competitiveness.
See More
FibroBiologics Regains Nasdaq Compliance with Key Requirements Met
- Compliance Restoration: FibroBiologics announced it has regained full compliance with Nasdaq listing rules by meeting the minimum $2.5 million stockholders' equity and $1.00 bid price requirements, ensuring the company continues to trade normally on Nasdaq.
- Monitoring Period: Although compliance issues are resolved, the company will still be under a one-year monitoring period, indicating Nasdaq's ongoing scrutiny of its future performance, which may affect investor confidence.
- Stock Performance: In after-hours trading, FBLG shares fell approximately $1.31 to $1.51, reflecting market reactions to the company's compliance restoration and potential future risks.
- Financing Strategy: FibroBiologics priced a combined unit offering at $4.40 and executed a 1-for-20 reverse split to further solidify its Nasdaq compliance status, demonstrating strategic adjustments in its capital structure.
See More
FibroBiologics Unveils Data on Reversing Immune Decline
- Immune Function Restoration: FibroBiologics' research indicates that its proprietary thymic organoid platform can reverse age-related immune decline by restoring thymic function, enhancing T cell production capacity, thereby improving the body's resistance to infections and cancer.
- Diverse T Cell Generation: In immunodeficient mouse models, transplanted thymic organoids successfully generated multiple T cell lineages, including αβ T cells and γδ T cells, demonstrating their biological activity and diversity in vivo, indicating potential for clinical applications.
- Anti-Tumor Activity: T cells derived from thymic organoids exhibited anti-tumor activity in a targeted cancer model against melanoma, slowing tumor growth and enhancing natural killer cell activation, suggesting a systemic immune response rather than localized effects.
- Clinical Application Prospects: The findings from FibroBiologics not only provide a new solution for age-related immune decline but also hold significant potential in recovery following chemotherapy or radiation, as well as in congenital disorders caused by loss of thymic function.
See More
FibroBiologics Presents Psoriasis Data at SID 2026
- Clinical Stage Progress: FibroBiologics presents preclinical data from its CYPS317 program for psoriasis at the 2026 Society for Investigative Dermatology Annual Meeting, highlighting the company's ongoing R&D efforts in psoriasis treatment, which is expected to enhance its competitiveness in the biotechnology sector.
- Patent Advantage: With over 270 issued and pending patents covering various chronic disease treatments, the company demonstrates its innovative capabilities in cell therapy and tissue regeneration, potentially laying the groundwork for future market expansion.
- Conference Details: Senior Scientist Dr. Chuo Fang will present at the annual meeting in Chicago on May 15, 2026, from 4:30 p.m. to 6:00 p.m., further elevating the company's profile in the academic community.
- Strategic Positioning: By showcasing preclinical data, FibroBiologics not only highlights its potential in psoriasis treatment but may also attract investor interest, facilitating future funding inflows to support its R&D projects.
See More
FibroBiologics Reports Q1 2026 Financial Results and Corporate Update
- Clinical Trial Progress: FibroBiologics has completed the manufacturing of the first two batches of the CYWC628 drug product in compliance with FDA cGMP, laying the groundwork for the phase 1/2 clinical trial for diabetic foot ulcers, with patient dosing expected to commence in Q2 2026.
- Positive Preclinical Results: The company reported promising preclinical outcomes in its burn program using proprietary fibroblast spheroid technology, indicating an increase in tissue repair cytokines and a significant reduction in inflammation drivers, suggesting strong therapeutic potential for future clinical applications.
- Funding and Compliance: FibroBiologics raised $3 million through a direct offering and secured an additional $2.5 million post-March 31, 2026, successfully regaining compliance with Nasdaq listing requirements, thereby enhancing the company's financial stability.
- Patent Portfolio Expansion: The company has expanded its patent portfolio with new patents covering fibroblast cell therapy for osteoporosis and a novel fibroblast-based treatment for cachexia, further solidifying its intellectual property in the biotechnology sector and supporting future product development.
See More
FibroBiologics Reports Q1 2026 Financial Results with $5M Loss
- Financial Loss Overview: FibroBiologics reported a net loss of approximately $5 million for the three months ended March 31, 2026, primarily due to increased research and development and administrative expenses, indicating ongoing investment in technology development amid financial pressure.
- Cash Flow Status: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, reflecting tight operational funding that may impact future research and operational capabilities.
- Financing Activities: After March 31, 2026, FibroBiologics raised approximately $2.5 million net through a registered direct offering, aimed at enhancing liquidity and supporting ongoing operations.
- Nasdaq Compliance: FibroBiologics successfully met Nasdaq's $2.5 million equity rule through a combined unit offering priced at $4.40 and a 1-for-20 reverse split, ensuring compliance in the capital markets.
See More
FibroBiologics Advances Phase 1/2 Clinical Trial for CYWC628
- Clinical Trial Launch: FibroBiologics is on track to dose the first patient with CYWC628 for diabetic foot ulcers in Q2 2026, marking a significant milestone in its clinical development and potentially enhancing its market position in chronic disease treatments.
- Manufacturing Compliance: The company has completed the production of the first two batches of CYWC628 in accordance with FDA Good Manufacturing Practices (cGMP), ensuring product quality and laying a solid foundation for the upcoming clinical trials.
- Financial Position Improvement: FibroBiologics raised $3 million through a direct offering in Q1 2026, bolstering its cash flow, and despite an increase in R&D expenses to $3 million, the company remains compliant, reflecting robust financial management.
- Patent Portfolio Expansion: The company has secured new patents for treatments targeting osteoporosis and cachexia, further strengthening its intellectual property in cell therapy, which is expected to provide significant support for future product development and market competitiveness.
See More
FibroBiologics Regains Nasdaq Compliance with Key Requirements Met
- Compliance Restoration: FibroBiologics announced it has regained full compliance with Nasdaq listing rules by meeting the minimum $2.5 million stockholders' equity and $1.00 bid price requirements, ensuring the company continues to trade normally on Nasdaq.
- Monitoring Period: Although compliance issues are resolved, the company will still be under a one-year monitoring period, indicating Nasdaq's ongoing scrutiny of its future performance, which may affect investor confidence.
- Stock Performance: In after-hours trading, FBLG shares fell approximately $1.31 to $1.51, reflecting market reactions to the company's compliance restoration and potential future risks.
- Financing Strategy: FibroBiologics priced a combined unit offering at $4.40 and executed a 1-for-20 reverse split to further solidify its Nasdaq compliance status, demonstrating strategic adjustments in its capital structure.
See More
FibroBiologics Unveils Data on Reversing Immune Decline
- Immune Function Restoration: FibroBiologics' research indicates that its proprietary thymic organoid platform can reverse age-related immune decline by restoring thymic function, enhancing T cell production capacity, thereby improving the body's resistance to infections and cancer.
- Diverse T Cell Generation: In immunodeficient mouse models, transplanted thymic organoids successfully generated multiple T cell lineages, including αβ T cells and γδ T cells, demonstrating their biological activity and diversity in vivo, indicating potential for clinical applications.
- Anti-Tumor Activity: T cells derived from thymic organoids exhibited anti-tumor activity in a targeted cancer model against melanoma, slowing tumor growth and enhancing natural killer cell activation, suggesting a systemic immune response rather than localized effects.
- Clinical Application Prospects: The findings from FibroBiologics not only provide a new solution for age-related immune decline but also hold significant potential in recovery following chemotherapy or radiation, as well as in congenital disorders caused by loss of thymic function.
See More
